Test Your Understanding Quiz 3

Prev
 1 / 17 
Next
Prev
 1 / 17 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • Identify which clinical features of cold agglutinin disease require treatment versus observation
  • Distinguish supportive measures from disease-modifying therapies
  • Select treatment strategies based on the dominant disease mechanism
  • Recognize clinical situations in which intervention is appropriate and match therapy to the underlying mechanism

A 72-year-old patient with known CAD reports mild fatigue but has a stable hemoglobin of 11.9 g/dL. The patient experiences occasional acrocyanosis during winter but no significant functional limitation.

Which management approach is most appropriate?

a
Immediate complement inhibition therapy
Complement inhibitors such as sutimlimab are generally reserved for patients with clinically significant hemolysis or symptomatic anemia.
b
Observation and cold-avoidance measures
Patients with mild disease (Hb ≥10–11 g/dL and manageable symptoms) are typically managed conservatively with cold avoidance and monitoring.
c
Urgent splenectomy
Splenectomy is usually ineffective in CAD because hemolysis occurs primarily in the liver rather than the spleen.
d
High-dose corticosteroids
Corticosteroids are often ineffective in CAD because the disease is driven primarily by IgM-mediated complement activation rather than IgG-mediated autoimmunity.

A patient with CAD develops worsening anemia with hemoglobin 7.6 g/dL and symptomatic fatigue.

Which mechanism is most directly responsible for the anemia?

a
Complement-mediated destruction of RBCs
Complement activation leads to RBC destruction, usually through extravascular clearance in the liver by Kupffer cells.
b
IgM-mediated RBC agglutination in peripheral vessels
Agglutination primarily causes circulatory symptoms rather than significant anemia.
c
Bone marrow suppression from autoimmune attack
Bone marrow suppression is not the primary mechanism in CAD.
d
Iron deficiency from chronic blood loss
Iron deficiency does not explain complement-positive hemolysis.

A patient with CAD has severe acrocyanosis but relatively mild anemia.

Which therapeutic approach most directly targets the dominant mechanism producing the symptoms?

a
Complement inhibition therapy
Complement inhibition primarily reduces hemolysis rather than circulatory symptoms.
b
Clone-directed B-cell therapy
lone-directed therapy (e.g., rituximab-based regimens) reduces antibody production but does not provide immediate relief of agglutination symptoms.
c
Cold avoidance and thermal protection
Avoiding cold exposure reduces IgM binding to RBCs and prevents agglutination in peripheral vessels.
d
Iron supplementation
Iron supplementation does not address the mechanism of symptoms.

Which treatment approach targets the source of antibody production in primary CAD?

a
Complement inhibition therapy
Complement inhibitors block downstream hemolysis but do not eliminate antibody production.
b
Clone-directed B-cell therapy
Clone-directed therapy targets the B-cell population producing the pathogenic IgM antibody, often using rituximab-based regimens.
c
Transfusion support
Transfusion replaces RBCs but does not modify the disease mechanism.
d
Thermal protection strategies
Thermal protection reduces symptoms but does not affect antibody production.

A patient with CAD develops worsening hemolysis following an infection.

Which mechanism most likely explains the deterioration?

a
Suppression of erythropoiesis
Suppressed erythropoiesis would worsen anemia but would not explain acute increases in hemolysis.
b
Decreased IgM antibody production
Reduced IgM production would improve disease.
c
Reduced hepatic clearance of RBCs
Reduced hepatic clearance would tend to decrease hemolysis.
d
Increased complement activation during inflammation
Inflammatory states can increase complement activity through the acute-phase response, amplifying complement-mediated hemolysis.

Which statement best explains why corticosteroids are usually ineffective in CAD?

a
CAD is primarily driven by complement activation rather than IgG-mediated autoimmunity
CAD pathophysiology is dominated by IgM-mediated complement activation, which responds poorly to corticosteroids compared with IgG-mediated warm AIHA. Steroids may occasionally be used as temporary bridging therapy but are not effective long-term treatment.
b
Corticosteroids suppress erythropoiesis
Corticosteroids do not primarily suppress erythropoiesis.
c
Corticosteroids increase IgM antibody production
Steroids do not increase IgM production.
d
Corticosteroids prevent complement deposition
Corticosteroids do not directly block complement deposition.

Why is splenectomy generally ineffective in treating CAD?

a
RBC destruction occurs primarily in the liver rather than the spleen
Complement-coated RBCs are removed mainly by hepatic macrophages (Kupffer cells) rather than splenic macrophages.
b
Complement activation cannot occur in the spleen
Complement activation occurs in the circulation.
c
IgM antibodies are produced exclusively in the spleen
IgM antibodies are produced by B cells in multiple lymphoid tissues.
d
Splenectomy increases complement activity
Splenectomy does not increase complement activity.

A patient with CAD requires RBC transfusion for symptomatic anemia.

Which precaution is most appropriate?

a
Administer transfusion at room temperature without modification
Cold blood products may trigger RBC agglutination in peripheral circulation.
b
Use warmed blood products during transfusion
Stored blood is kept at approximately 4 °C. Using a blood warmer prevents temperature-dependent IgM binding and reduces agglutination risk during transfusion.
c
Avoid transfusion entirely
Transfusion may be necessary in severe anemia.
d
Begin rituximab before transfusion
Rituximab does not prevent immediate transfusion complications.

A patient with CAD has persistent anemia despite rituximab therapy.

Which therapy most directly targets the remaining mechanism of disease?

a
Splenectomy
Splenectomy does not address complement-mediated hemolysis.
b
Corticosteroids
Corticosteroids have limited efficacy in CAD.
c
Iron supplementation
Iron supplementation does not address immune hemolysis.
d
Complement inhibition therapy
Complement inhibitors such as sutimlimab block early classical pathway activation and rapidly reduce hemolysis.

Notes

A patient with CAD reports worsening symptoms during winter but minimal problems during warmer months.

Which strategy is most appropriate as first-line management?

a
Aggressive immunosuppressive therapy
Immunosuppressive therapy is unnecessary for mild seasonal symptoms.
b
Complement inhibition therapy
Complement inhibitors are typically reserved for significant hemolysis.
c
Environmental and thermal protection
Avoiding cold exposure reduces antibody binding and agglutination.
d
Rituximab monotherapy
Rituximab is used for disease-modifying therapy when symptoms or hemolysis warrant treatment.

Sort the following interventions according to their primary purpose.

Rituximab
Cold avoidance
Complement inhibition
Thermal protection
Blood transfusion
Clone-directed therapy
Supportive measures
Disease-modifying therapies

Match the treatment strategy with its mechanistic target.

Complement inhibition
Thermal protection
Clone-directed B-cell therapy
Reduces complement-mediated hemolysis
Prevents cold-induced RBC agglutination
Decreases production of pathogenic IgM antibodies
Correct! Sorry, Incorrect.

Closing Note

Managing cold agglutinin disease requires identifying the mechanism driving the patient’s symptoms.

Circulatory symptoms arise from IgM-mediated agglutination, while anemia reflects complement-mediated hemolysis.

Effective care depends on matching the treatment to the dominant mechanism.

Prev
 1 / 17 
Next